Dendrite Raises Financial Aid for Disaster Relief Effort in South and South-East Asia; More Than $70,000 in Relief Funds Donated Through Direct Relief International.

BEDMINSTER, N.J. -- Dendrite International, Inc. (NASDAQ: DRTE), a leading provider of sales, marketing, clinical and compliance solutions for the life sciences industry, today announced that it joined the international effort to help bring relief to the victims of the Indian Ocean tsunami that caused immense devastation in that area recently. Dendrite raised more than $70,000 in employee and company-matched contributions. The donations to the relief effort were made through Direct Relief International (DRI) a distinguished organization that has been leading worldwide assistance efforts since 1948.

"One of the most rewarding aspects of working at Dendrite is to see the way our employees around the world help others in a time of crisis," said Paul Zaffaroni, President and Chief Operating Officer at Dendrite. "Our employees demonstrated an outstanding level of generosity that will help the people of South and South-East Asia rebuild their homes, get the necessary medical attention, food and clothing they need."

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) provides award-winning sales, marketing, clinical and compliance solutions and services to the global life sciences and pharmaceutical industry. With clients in more than 50 countries, including the world's top 20 pharmaceutical companies, Dendrite strives to be the first source for expert solutions and services that drive promotional and sales effectiveness to life science and pharmaceutical companies. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.